Department of Endocrinology and Nutrition, Quirón Salud Madrid and Ruber Juan Bravo University Hospitals, Universidad Europea de Madrid, Madrid, Spain.
Department of Internal Medicine, Endocrine Section, Clínica Universidad de los Andes and School of Medicine, Universidad de los Andes, Santiago, Chile.
Eur J Nutr. 2023 Jun;62(4):1579-1597. doi: 10.1007/s00394-023-03103-1. Epub 2023 Mar 2.
In addition to the role of vitamin D in bone mineralization, calcium and phosphate homeostasis, and skeletal health, evidence suggests an association between vitamin D deficiency and a wide range of chronic conditions. This is of clinical concern given the substantial global prevalence of vitamin D deficiency. Vitamin D deficiency has traditionally been treated with vitamin D (cholecalciferol) or vitamin D (ergocalciferol). Calcifediol (25-hydroxyvitamin D) has recently become available more widely.
By means of targeted literature searches of PubMed, this narrative review overviews the physiological functions and metabolic pathways of vitamin D, examines the differences between calcifediol and vitamin D, and highlights clinical trials conducted with calcifediol in patients with bone disease or other conditions.
For supplemental use in the healthy population, calcifediol can be used at doses of up to 10 µg per day for children ≥ 11 years and adults and up to 5 µg/day in children 3-10 years. For therapeutic use of calcifediol under medical supervision, the dose, frequency and duration of treatment is determined according to serum 25(OH)D concentrations, condition, type of patient and comorbidities. Calcifediol differs pharmacokinetically from vitamin D in several ways. It is independent of hepatic 25-hydroxylation and thus is one step closer in the metabolic pathway to active vitamin D. At comparable doses to vitamin D, calcifediol achieves target serum 25(OH)D concentrations more rapidly and in contrast to vitamin D, it has a predictable and linear dose-response curve irrespective of baseline serum 25(OH)D concentrations. The intestinal absorption of calcifediol is relatively preserved in patients with fat malabsorption and it is more hydrophilic than vitamin D and thus is less prone to sequestration in adipose tissue.
Calcifediol is suitable for use in all patients with vitamin D deficiency and may be preferable to vitamin D for patients with obesity, liver disease, malabsorption and those who require a rapid increase in 25(OH)D concentrations.
除了在骨矿化、钙磷稳态和骨骼健康方面发挥作用外,维生素 D 缺乏与广泛的慢性疾病之间也存在关联,这一证据提示人们需要关注维生素 D 缺乏问题。鉴于维生素 D 缺乏在全球范围内的高发病率,这一情况具有重要的临床意义。传统上,维生素 D(胆钙化醇)或维生素 D(麦角钙化醇)用于治疗维生素 D 缺乏症。最近,25-羟维生素 D(calcifediol)的应用更加广泛。
通过对 PubMed 的有针对性的文献检索,本综述概述了维生素 D 的生理功能和代谢途径,比较了 calcifediol 和维生素 D 之间的差异,并重点介绍了在患有骨骼疾病或其他疾病的患者中进行的 calcifediol 临床试验。
对于健康人群的补充使用,calcifediol 的剂量可达儿童(≥11 岁)和成人每天 10μg,3-10 岁儿童每天 5μg。在医疗监督下,根据血清 25(OH)D 浓度、病情、患者类型和合并症等因素,确定 calcifediol 的剂量、频率和治疗持续时间。Calcifediol 在几个方面与维生素 D 在药代动力学上有所不同。它不依赖于肝脏 25-羟化,因此在代谢途径上更接近活性维生素 D。与维生素 D 相比,在相当剂量下,calcifediol 能更快地达到目标血清 25(OH)D 浓度,并且与维生素 D 不同,它具有可预测的线性剂量反应曲线,而与基线血清 25(OH)D 浓度无关。Calcifediol 的肠吸收在脂肪吸收不良的患者中相对保留,并且它比维生素 D 更亲水,因此不易被脂肪组织隔离。
Calcifediol 适用于所有维生素 D 缺乏症患者,对于肥胖、肝病、吸收不良和需要快速增加 25(OH)D 浓度的患者,calcifediol 可能优于维生素 D。